Rivian Automotive Inc

NASDAQ:RIVNUnited States

Today

Show headlines and story abstract

• The Gross Law Firm Reminds Rivian Automotive, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 30, 2024 - RIVN, from 53 minutes ago by PR Newswire

  53 minutes ago by PR Newswire
  Companies Mentioned: RIVN

  The Gross Law Firm issues the following notice to shareholders of Rivian Automotive, Inc. (NASDAQ: RIVN).

  https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg

  Shareholders who purchased shares of RIVN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

• The Gross Law Firm Reminds Rivian Automotive, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 30, 2024 - RIVN, from 53 minutes ago by Dow Jones

  53 minutes ago by Dow Jones
  Companies Mentioned: RIVN
  
  The Gross Law Firm Reminds Rivian Automotive, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 30, 2024 - RIVN
  
  PR Newswire
  
  

• Lifshitz Law PLLC Announces Investigations of Akero Therapeutics, Inc. (NASDAQ: AKRO), Rivian Automotive, Inc. (NASDAQ: RIVN), Autodesk, Inc. (NASDAQ: ADSK), and NIKE, Inc. (NYSE: NKE), from 5 hours ago by Accesswire

  5 hours ago by Accesswire
  Companies Mentioned: ADSK, AKRO, RIVN

  NEW YORK, NY / ACCESSWIRE / July 3, 2023 / Lifshitz Law Firm

  Akero Therapeutics, Inc. (NASDAQ:AKRO)

  Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose material information that: (i) approximately 20% of the patients enrolled in its SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline; (ii) the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definitive NASH; (iii) the results from the cryptogenic cirrhosis patients were to be excluded from the calculation of the NASH resolution secondary endpoints; (iv) Akero had introduced a confounding factor into the SYMMETRY study's design, materially influencing the study's potential results and increasing the risks that the study would fail to meet its primary endpoint; (v) the SYMMETRY study did not align with U.S. Food & Drug Administration guidance for testing a drug in treating NASH cirrhotics because Akero had not ruled out potential causes of each patient's cirrhosis other than NASH; and (vi) consequently, Akero had materially misrepresented the nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood that EFX would become a commercial treatment for NASH cirrhotics.

• Lifshitz Law PLLC Announces Investigations of Akero Therapeutics, Inc. (NASDAQ: AKRO), Rivian Automotive, Inc. (NASDAQ: RIVN), Autodesk, Inc. (NASDAQ: ADSK), and NIKE, Inc. (NYSE: NKE), from 5 hours ago by Dow Jones

  5 hours ago by Dow Jones
  Companies Mentioned: NKE, ADSK, AKRO, RIVN
  
  NEW YORK, NY / ACCESSWIRE / July 3, 2023 / Lifshitz Law Firm
  
  Akero Therapeutics, Inc. (NASDAQ:AKRO)
  
  Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose material information that: (i) approximately 20% of the patients enrolled in its SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline; (ii) the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definitive NASH; (iii) the results from the cryptogenic cirrhosis patients were to be excluded from the calculation of the NASH resolution secondary endpoints; (iv) Akero had introduced a confounding factor into the SYMMETRY study's design, materially influencing the study's potential results and increasing the risks that the study would fail to meet its primary endpoint; (v) the SYMMETRY study did not align with U.S. Food & Drug Administration guidance for testing a drug in treating NASH cirrhotics because Akero had not ruled out potential causes of each patient's cirrhosis other than NASH; and (vi) consequently, Akero had materially misrepresented the nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood that EFX would become a commercial treatment for NASH cirrhotics.